SrasV1, PubMed, Curation, bibRecord, 001973

Delivery to the lower respiratory tract is required for effective immunization with Newcastle disease virus-vectored vaccines intended for humans.

Identifieur interne : 001973 ( PubMed/Curation ); précédent : 001972; suivant : 001974

Delivery to the lower respiratory tract is required for effective immunization with Newcastle disease virus-vectored vaccines intended for humans.

Auteurs : Joshua M. Dinapoli [États-Unis] ; Jerrold M. Ward ; Lily Cheng ; Lijuan Yang ; Subbiah Elankumaran ; Brian R. Murphy ; Siba K. Samal ; Peter L. Collins ; Alexander Bukreyev

Source :

Vaccine [ 0264-410X ] ; 2009.

RBID : pubmed:19168110

Descripteurs français

KwdFr :
- Animaux, Humains, Poumon (anatomopathologie), Poumon (immunologie), Vaccination (), Vaccins antiviraux (administration et posologie), Vaccins antiviraux (génétique), Vaccins antiviraux (immunologie), Vaccins synthétiques (administration et posologie), Vaccins synthétiques (génétique), Vaccins synthétiques (immunologie), Vecteurs génétiques, Virus de la maladie de Newcastle (génétique), Virus de la maladie de Newcastle (immunologie), Virus du SRAS (génétique), Virus du SRAS (immunologie).
MESH :
- administration et posologie : Vaccins antiviraux, Vaccins synthétiques.
- anatomopathologie : Poumon.
- génétique : Vaccins antiviraux, Vaccins synthétiques, Virus de la maladie de Newcastle, Virus du SRAS.
- immunologie : Poumon, Vaccins antiviraux, Vaccins synthétiques, Virus de la maladie de Newcastle, Virus du SRAS.
- Animaux, Humains, Vaccination, Vecteurs génétiques.

English descriptors

KwdEn :
- Animals, Chlorocebus aethiops, Genetic Vectors, Humans, Lung (immunology), Lung (pathology), Newcastle disease virus (genetics), Newcastle disease virus (immunology), SARS Virus (genetics), SARS Virus (immunology), Vaccination (methods), Vaccines, Synthetic (administration & dosage), Vaccines, Synthetic (genetics), Vaccines, Synthetic (immunology), Viral Vaccines (administration & dosage), Viral Vaccines (genetics), Viral Vaccines (immunology).
MESH :
- chemical , administration & dosage : Vaccines, Synthetic, Viral Vaccines.
- genetics : Newcastle disease virus, SARS Virus, Vaccines, Synthetic, Viral Vaccines.
- immunology : Lung, Newcastle disease virus, SARS Virus, Vaccines, Synthetic, Viral Vaccines.
- methods : Vaccination.
- pathology : Lung.
- Animals, Chlorocebus aethiops, Genetic Vectors, Humans.

Abstract

Newcastle disease virus (NDV), an avian virus, is being evaluated for the development of vectored human vaccines against emerging pathogens. Previous studies of NDV-vectored vaccines in a mouse model suggested their potency after delivery by injection or by the intranasal route. We compared the efficacy of various routes of delivery of NDV-vectored vaccines in a non-human primate model. While delivery of an NDV-vectored vaccine by the combined intranasal/intratracheal route elicited protective immune responses, delivery by the subcutaneous route or the intranasal route alone elicited limited or no protective immune responses, suggesting the necessity for vaccine delivery to the lower respiratory tract. Furthermore, direct comparison of a vaccine based on an NDV mesogenic strain (NDV-BC) with a similarly designed NDV vector based on a modified lentogenic strain carrying a polybasic F cleavage site (NDV-VF) suggested that the two NDV strains were similar in immunogenicity and were equally protective.

DOI: 10.1016/j.vaccine.2009.01.009
PubMed: 19168110

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001973

Links to Exploration step

pubmed:19168110

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Delivery to the lower respiratory tract is required for effective immunization with Newcastle disease virus-vectored vaccines intended for humans.</title>
<author><name sortKey="Dinapoli, Joshua M" sort="Dinapoli, Joshua M" uniqKey="Dinapoli J" first="Joshua M" last="Dinapoli">Joshua M. Dinapoli</name>
<affiliation wicri:level="1"><nlm:affiliation>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892-8007, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892-8007</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Ward, Jerrold M" sort="Ward, Jerrold M" uniqKey="Ward J" first="Jerrold M" last="Ward">Jerrold M. Ward</name>
</author>
<author><name sortKey="Cheng, Lily" sort="Cheng, Lily" uniqKey="Cheng L" first="Lily" last="Cheng">Lily Cheng</name>
</author>
<author><name sortKey="Yang, Lijuan" sort="Yang, Lijuan" uniqKey="Yang L" first="Lijuan" last="Yang">Lijuan Yang</name>
</author>
<author><name sortKey="Elankumaran, Subbiah" sort="Elankumaran, Subbiah" uniqKey="Elankumaran S" first="Subbiah" last="Elankumaran">Subbiah Elankumaran</name>
</author>
<author><name sortKey="Murphy, Brian R" sort="Murphy, Brian R" uniqKey="Murphy B" first="Brian R" last="Murphy">Brian R. Murphy</name>
</author>
<author><name sortKey="Samal, Siba K" sort="Samal, Siba K" uniqKey="Samal S" first="Siba K" last="Samal">Siba K. Samal</name>
</author>
<author><name sortKey="Collins, Peter L" sort="Collins, Peter L" uniqKey="Collins P" first="Peter L" last="Collins">Peter L. Collins</name>
</author>
<author><name sortKey="Bukreyev, Alexander" sort="Bukreyev, Alexander" uniqKey="Bukreyev A" first="Alexander" last="Bukreyev">Alexander Bukreyev</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2009">2009</date>
<idno type="RBID">pubmed:19168110</idno>
<idno type="pmid">19168110</idno>
<idno type="doi">10.1016/j.vaccine.2009.01.009</idno>
<idno type="wicri:Area/PubMed/Corpus">001973</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001973</idno>
<idno type="wicri:Area/PubMed/Curation">001973</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001973</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Delivery to the lower respiratory tract is required for effective immunization with Newcastle disease virus-vectored vaccines intended for humans.</title>
<author><name sortKey="Dinapoli, Joshua M" sort="Dinapoli, Joshua M" uniqKey="Dinapoli J" first="Joshua M" last="Dinapoli">Joshua M. Dinapoli</name>
<affiliation wicri:level="1"><nlm:affiliation>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892-8007, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892-8007</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Ward, Jerrold M" sort="Ward, Jerrold M" uniqKey="Ward J" first="Jerrold M" last="Ward">Jerrold M. Ward</name>
</author>
<author><name sortKey="Cheng, Lily" sort="Cheng, Lily" uniqKey="Cheng L" first="Lily" last="Cheng">Lily Cheng</name>
</author>
<author><name sortKey="Yang, Lijuan" sort="Yang, Lijuan" uniqKey="Yang L" first="Lijuan" last="Yang">Lijuan Yang</name>
</author>
<author><name sortKey="Elankumaran, Subbiah" sort="Elankumaran, Subbiah" uniqKey="Elankumaran S" first="Subbiah" last="Elankumaran">Subbiah Elankumaran</name>
</author>
<author><name sortKey="Murphy, Brian R" sort="Murphy, Brian R" uniqKey="Murphy B" first="Brian R" last="Murphy">Brian R. Murphy</name>
</author>
<author><name sortKey="Samal, Siba K" sort="Samal, Siba K" uniqKey="Samal S" first="Siba K" last="Samal">Siba K. Samal</name>
</author>
<author><name sortKey="Collins, Peter L" sort="Collins, Peter L" uniqKey="Collins P" first="Peter L" last="Collins">Peter L. Collins</name>
</author>
<author><name sortKey="Bukreyev, Alexander" sort="Bukreyev, Alexander" uniqKey="Bukreyev A" first="Alexander" last="Bukreyev">Alexander Bukreyev</name>
</author>
</analytic>
<series><title level="j">Vaccine</title>
<idno type="ISSN">0264-410X</idno>
<imprint><date when="2009" type="published">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Chlorocebus aethiops</term>
<term>Genetic Vectors</term>
<term>Humans</term>
<term>Lung (immunology)</term>
<term>Lung (pathology)</term>
<term>Newcastle disease virus (genetics)</term>
<term>Newcastle disease virus (immunology)</term>
<term>SARS Virus (genetics)</term>
<term>SARS Virus (immunology)</term>
<term>Vaccination (methods)</term>
<term>Vaccines, Synthetic (administration & dosage)</term>
<term>Vaccines, Synthetic (genetics)</term>
<term>Vaccines, Synthetic (immunology)</term>
<term>Viral Vaccines (administration & dosage)</term>
<term>Viral Vaccines (genetics)</term>
<term>Viral Vaccines (immunology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Humains</term>
<term>Poumon (anatomopathologie)</term>
<term>Poumon (immunologie)</term>
<term>Vaccination ()</term>
<term>Vaccins antiviraux (administration et posologie)</term>
<term>Vaccins antiviraux (génétique)</term>
<term>Vaccins antiviraux (immunologie)</term>
<term>Vaccins synthétiques (administration et posologie)</term>
<term>Vaccins synthétiques (génétique)</term>
<term>Vaccins synthétiques (immunologie)</term>
<term>Vecteurs génétiques</term>
<term>Virus de la maladie de Newcastle (génétique)</term>
<term>Virus de la maladie de Newcastle (immunologie)</term>
<term>Virus du SRAS (génétique)</term>
<term>Virus du SRAS (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Vaccines, Synthetic</term>
<term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antiviraux</term>
<term>Vaccins synthétiques</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Poumon</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Newcastle disease virus</term>
<term>SARS Virus</term>
<term>Vaccines, Synthetic</term>
<term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Vaccins antiviraux</term>
<term>Vaccins synthétiques</term>
<term>Virus de la maladie de Newcastle</term>
<term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Poumon</term>
<term>Vaccins antiviraux</term>
<term>Vaccins synthétiques</term>
<term>Virus de la maladie de Newcastle</term>
<term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Lung</term>
<term>Newcastle disease virus</term>
<term>SARS Virus</term>
<term>Vaccines, Synthetic</term>
<term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Vaccination</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Lung</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Chlorocebus aethiops</term>
<term>Genetic Vectors</term>
<term>Humans</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Humains</term>
<term>Vaccination</term>
<term>Vecteurs génétiques</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Newcastle disease virus (NDV), an avian virus, is being evaluated for the development of vectored human vaccines against emerging pathogens. Previous studies of NDV-vectored vaccines in a mouse model suggested their potency after delivery by injection or by the intranasal route. We compared the efficacy of various routes of delivery of NDV-vectored vaccines in a non-human primate model. While delivery of an NDV-vectored vaccine by the combined intranasal/intratracheal route elicited protective immune responses, delivery by the subcutaneous route or the intranasal route alone elicited limited or no protective immune responses, suggesting the necessity for vaccine delivery to the lower respiratory tract. Furthermore, direct comparison of a vaccine based on an NDV mesogenic strain (NDV-BC) with a similarly designed NDV vector based on a modified lentogenic strain carrying a polybasic F cleavage site (NDV-VF) suggested that the two NDV strains were similar in immunogenicity and were equally protective.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19168110</PMID>
<DateCompleted><Year>2009</Year>
<Month>05</Month>
<Day>01</Day>
</DateCompleted>
<DateRevised><Year>2019</Year>
<Month>12</Month>
<Day>10</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0264-410X</ISSN>
<JournalIssue CitedMedium="Print"><Volume>27</Volume>
<Issue>10</Issue>
<PubDate><Year>2009</Year>
<Month>Mar</Month>
<Day>04</Day>
</PubDate>
</JournalIssue>
<Title>Vaccine</Title>
<ISOAbbreviation>Vaccine</ISOAbbreviation>
</Journal>
<ArticleTitle>Delivery to the lower respiratory tract is required for effective immunization with Newcastle disease virus-vectored vaccines intended for humans.</ArticleTitle>
<Pagination><MedlinePgn>1530-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2009.01.009</ELocationID>
<Abstract><AbstractText>Newcastle disease virus (NDV), an avian virus, is being evaluated for the development of vectored human vaccines against emerging pathogens. Previous studies of NDV-vectored vaccines in a mouse model suggested their potency after delivery by injection or by the intranasal route. We compared the efficacy of various routes of delivery of NDV-vectored vaccines in a non-human primate model. While delivery of an NDV-vectored vaccine by the combined intranasal/intratracheal route elicited protective immune responses, delivery by the subcutaneous route or the intranasal route alone elicited limited or no protective immune responses, suggesting the necessity for vaccine delivery to the lower respiratory tract. Furthermore, direct comparison of a vaccine based on an NDV mesogenic strain (NDV-BC) with a similarly designed NDV vector based on a modified lentogenic strain carrying a polybasic F cleavage site (NDV-VF) suggested that the two NDV strains were similar in immunogenicity and were equally protective.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>DiNapoli</LastName>
<ForeName>Joshua M</ForeName>
<Initials>JM</Initials>
<AffiliationInfo><Affiliation>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892-8007, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ward</LastName>
<ForeName>Jerrold M</ForeName>
<Initials>JM</Initials>
</Author>
<Author ValidYN="Y"><LastName>Cheng</LastName>
<ForeName>Lily</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y"><LastName>Yang</LastName>
<ForeName>Lijuan</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y"><LastName>Elankumaran</LastName>
<ForeName>Subbiah</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y"><LastName>Murphy</LastName>
<ForeName>Brian R</ForeName>
<Initials>BR</Initials>
</Author>
<Author ValidYN="Y"><LastName>Samal</LastName>
<ForeName>Siba K</ForeName>
<Initials>SK</Initials>
</Author>
<Author ValidYN="Y"><LastName>Collins</LastName>
<ForeName>Peter L</ForeName>
<Initials>PL</Initials>
</Author>
<Author ValidYN="Y"><LastName>Bukreyev</LastName>
<ForeName>Alexander</ForeName>
<Initials>A</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>Z01 AI000938-04</GrantID>
<Agency>Intramural NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>Z99 AI999999</GrantID>
<Agency>Intramural NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2009</Year>
<Month>01</Month>
<Day>23</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>Vaccine</MedlineTA>
<NlmUniqueID>8406899</NlmUniqueID>
<ISSNLinking>0264-410X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014614">Vaccines, Synthetic</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005822" MajorTopicYN="Y">Genetic Vectors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009522" MajorTopicYN="N">Newcastle disease virus</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014614" MajorTopicYN="N">Vaccines, Synthetic</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year>
<Month>09</Month>
<Day>24</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2008</Year>
<Month>12</Month>
<Day>24</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2009</Year>
<Month>01</Month>
<Day>05</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2009</Year>
<Month>1</Month>
<Day>27</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2009</Year>
<Month>1</Month>
<Day>27</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2009</Year>
<Month>5</Month>
<Day>2</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">19168110</ArticleId>
<ArticleId IdType="pii">S0264-410X(09)00022-X</ArticleId>
<ArticleId IdType="doi">10.1016/j.vaccine.2009.01.009</ArticleId>
<ArticleId IdType="pmc">PMC2723768</ArticleId>
<ArticleId IdType="mid">NIHMS102265</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Laryngoscope. 2000 Apr;110(4):651-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10764013</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Opin Mol Ther. 2008 Feb;10(1):46-55</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18228181</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bull World Health Organ. 2002;80(10):806-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12471401</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pediatr Infect Dis J. 2003 May;22(5):394-405</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12792378</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Microb Pathog. 2004 Jan;36(1):1-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14643634</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2004 Mar 15;172(6):3745-57</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15004179</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2004 Jun 26;363(9427):2122-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15220033</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2004 Sep;78(17):9366-75</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15308731</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 1982 Dec 24;218(4579):1330-2</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6183749</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 1984 Mar 31;1(8379):705-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6143042</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Virol. 1988 Oct;26(2):153-62</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3183639</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 1988 Dec;158(6):1209-19</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3198936</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 1995 Dec;172(6):1445-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7594701</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 1999 Jun;73(6):5001-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10233962</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2004 Dec 5;330(1):8-15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15527829</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2005 Apr 1;191(7):1093-104</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15747245</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2005 Nov;79(21):13275-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16227250</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2006 Feb;80(3):1130-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16414990</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2006 Mar 23;440(7083):435-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16554799</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Glycoconj J. 2006 Feb;23(1-2):5-17</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16575518</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2006 Nov;80(21):10293-306</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17041210</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2007 Jun 5;104(23):9788-93</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17535926</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2007 Nov;81(21):11560-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17715243</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2001 Dec;75(23):11868-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11689668</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001973 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001973 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PubMed
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:19168110
   |texte=   Delivery to the lower respiratory tract is required for effective immunization with Newcastle disease virus-vectored vaccines intended for humans.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i   -Sk "pubmed:19168110" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Delivery to the lower respiratory tract is required for effective immunization with Newcastle disease virus-vectored vaccines intended for humans.

Delivery to the lower respiratory tract is required for effective immunization with Newcastle disease virus-vectored vaccines intended for humans.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki